Messenger RNA (mRNA) News and Research

RSS

Breastfeeding women and their babies: the outcomes after mRNA COVID-19 vaccination

Scientists evaluated the effect of vaccination in breastfeeding women and its possible effects in infants in a study involving 180 fully vaccinated, breastfeeding women.

10 Sep 2021

Study finds no serious side effects of mRNA COVID-19 vaccines in lactating women, breastfed infants

In December 2020, two novel messenger RNA (mRNA) vaccines for SARS-CoV-2 received emergency use authorization from the U.S. Food and Drug Administration; however, the early trials excluded lactating women, leading to questions about their safety in this specific population.

8 Sep 2021

The tale of mRNA vaccines: Turning calamity into opportunity

In a review paper published in the journal Nature Reviews, researchers from Carnegie Mellon University and the University of Pennsylvania have described the underlying technologies for mRNA vaccines and their future prospects with improved delivery systems and applications in diseases beyond the ongoing COVID-19 pandemic.

31 Aug 2021

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

A recent study, available on the bioRxiv* preprint server, investigated the durability of cellular immune memory after mRNA vaccination against SARS-CoV-2 and whether booster jabs affect the durability of different immune response components. The study included testing for antibodies and cellular immune responses in covid patients and recovered individuals.

31 Aug 2021

Can SARS-CoV-2 be transmitted in the food cold chain?

A new study reports that the risk of transmitting SARS-CoV-2 through such fomites is very low.

30 Aug 2021

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Self-amplifying RNA (saRNA) is an advanced platform for nucleic acid vaccine development. The backbone is typically derived from an alphaviral genome and encodes a gene of interest (GOI) and a viral replicase that can amplify the genomic and subgenomic RNA.

30 Aug 2021

Large Israeli study offers detailed look at safety profile of mRNA vaccine against SARS-CoV-2

A deep look into a nationwide mass vaccination setting in Israel revealed that the BNT162b2 (Pfizer–BioNTech) vaccine is not linked with an elevated risk of a majority of the adverse events under study, with the exception of myocarditis. However, even that potentially severe adverse event is much more pervasive following the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), found a new study published in the New England Journal of Medicine (NEJM).

30 Aug 2021

Two mRNA vaccines are effective even without post-shot symptoms or prior SARS-CoV-2 infection

Vaccination with the two messenger RNA (mRNA) vaccines for SARS-CoV-2, the virus that causes COVID-19, yields a robust antibody response, even if a person did not develop significant symptoms following vaccination or did not have a prior SARS-CoV-2 infection.

26 Aug 2021

Compounds from medicinal mushrooms may be our future weapon against SARS-CoV-2

Certain steroid-like compounds from Taiwan's endemic medicinal mushrooms (known as antcins) may inhibit a host cell receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and, thus, prevent viral infection and subsequent development of the coronavirus disease (COVID-19), reports a new study published in the MDPI's journal Plants.

24 Aug 2021

Study pinpoints an enzyme with a significant impact on SARS-CoV-2 replication

By applying a systems biology approach, a recent bioRxiv* preprint research paper by scientists from the Icahn School of Medicine at Mount Sinai in New York unveils interactions between the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) and p38 mitogen-activated protein kinase (MAPK) pathway responsible for regulating the expression of crucial inflammatory mediators in human lung epithelial cells.

23 Aug 2021

COVID booster shots might be needed in subgroup of HIV-positive individuals

The coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic destroying lives and economies. COVID-19 is not curable, so vaccines are the only safeguard during this pandemic.

23 Aug 2021

Study examines COVID vaccination in California state prisons

In a new retrospective cohort study, researchers determined the efficacy of mRNA vaccines against COVID-19 among incarcerated people in California.

22 Aug 2021

Penn researchers reveal complex details of T-cell responses to mRNA COVID-19 vaccines

Messenger-RNA (mRNA) vaccines against the coronavirus that causes COVID-19 provoke a swift and strong response by the immune system's T cells - the heavy armor of the immune system - according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

16 Aug 2021

COVID-19 vaccine likely protects people living with HIV, study shows

A Johns Hopkins Medicine research team has shown that people living with the human immunodeficiency virus (HIV) are likely to be protected against SARS-CoV-2, the virus that causes COVID-19, if they are fully vaccinated.

11 Aug 2021

A new promising target for broad-spectrum therapeutics against coronaviruses

A recent study by Canadian and US researchers demonstrates how frameshift signals of coronaviruses represent a viable target for developing novel therapeutics with broad-spectrum activity – not only against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but also other constituents of the coronavirus family. The study is currently available on the bioRxiv* preprint server while it undergoes peer review.

11 Aug 2021

Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

A potential new treatment for mast cell cancers reduces the number of mast cells by "mutating" the messenger RNA (mRNA) before it can deliver instructions for manufacturing the gene responsible for cell proliferation.

10 Aug 2021

Study of antibody responses to COVID-19 mRNA vaccine in convalescent individuals

In addition to clinical trials conducted to determine the safety and efficacy of the mRNA vaccines, additional studies began describing the serological response to the vaccines under "real-world" conditions, especially with the onset of the SARS-CoV-2 variants and case reports of vaccine escape.

9 Aug 2021

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Researchers in Singapore have conducted a study showing that the messenger RNA- (mRNA) based coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna are highly effective at protecting against symptomatic and severe disease following infection with the rapidly spreading B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

A new study published in The New England Journal of Medicine found that in a very small number of cases, people with breakthrough infections might suffer long-lasting COVID-19 symptoms.

2 Aug 2021

Finding potential microRNAs from humans and plants against SARS-CoV-2

A new study focuses on the identification of probable miRNA candidates from three medicinal plants.

1 Aug 2021

Messenger RNA (mRNA) News and Research

Breastfeeding women and their babies: the outcomes after mRNA COVID-19 vaccination

Study finds no serious side effects of mRNA COVID-19 vaccines in lactating women, breastfed infants

The tale of mRNA vaccines: Turning calamity into opportunity

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

Can SARS-CoV-2 be transmitted in the food cold chain?

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Large Israeli study offers detailed look at safety profile of mRNA vaccine against SARS-CoV-2

Two mRNA vaccines are effective even without post-shot symptoms or prior SARS-CoV-2 infection

Compounds from medicinal mushrooms may be our future weapon against SARS-CoV-2

Study pinpoints an enzyme with a significant impact on SARS-CoV-2 replication

COVID booster shots might be needed in subgroup of HIV-positive individuals

Study examines COVID vaccination in California state prisons

Penn researchers reveal complex details of T-cell responses to mRNA COVID-19 vaccines

COVID-19 vaccine likely protects people living with HIV, study shows

A new promising target for broad-spectrum therapeutics against coronaviruses

Potential new treatment for mast cell cancers reduces tumor size and prevents organ infiltration

Study of antibody responses to COVID-19 mRNA vaccine in convalescent individuals

Study shows efficacy of Pfizer-BioNTech and Moderna vaccines against SARS-CoV-2 delta variant

Study examined 1,497 full-vaccinated healthcare workers for breakthrough infections

Finding potential microRNAs from humans and plants against SARS-CoV-2

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring